Discount PBS prescriptions started January 1 in Australia

4 January 2016
australia-big

January 1 marked the start of landmark competition reforms in the Australian medicines sector, whereby pharmacists are able to discount the cost of a prescription subsidized through the government’s Pharmaceutical Benefits Scheme (PBS) for the first time.

Minister for Health Sussan Ley announced that consumers could now access discounts of up to A$1 on every PBS-subsidised script they purchased throughout the year – potentially saving patients upwards of A$70 (~$51) annually.

Ms Ley said pensioners and other concession card holders would particularly benefit, given 80% of PBS scripts were concessional, and would see their co-payment potentially fall from $6.20 to $5.20. Ms Ley said she had been buoyed by the significant number and variety of pharmacy chains – not just large-scale discounters – who had already announced they would offer patients some form of discount and encouraged interested consumers to shop around for the best deal.

Other measures under agreement with Pharmacy Guild

Ms Ley said the $1 PBS script discount was one of a number of positive measures for consumers included in the five-year $18.9 billion Sixth Community Agreement, which was agreed to, and signed, between the government and the Pharmacy Guild of Australia. She said other positive measures in the agreement agreed to by the Pharmacy Guild, included:

  • A$1.2 billion taxpayer investment to support pharmacists to undertake primary care services for patients – double that invested in the previous 5CPA agreement.
  • A$1.5 billion taxpayer investment to support the introduction of a new, transparent, fixed-price handling fee to give pharmacists remuneration stability and certainty, and complement the ability for pharmacists to introduce discounting of PBS prescriptions.
  • Better targeting the premium-free dispensing incentive to promote the uptake of cheaper generic medicines for consumers.
  • An independent review of pharmacy remuneration and location rules, which dictate where a pharmacy can and cannot open.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical